Cardiac Magnetic Resonance Imaging and Pulmonary Perfusion

Cardiac Magnetic Resonance Imaging and Pulmonary Perfusion: Its Role in the Diagnosis of the Severity of Pulmonary Hypertension in Adults and in the Follow-up. Preliminary Study.

Status

Completed

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT01100008

Enrollment

Registered

2010-04-08

Start date

2007-09-30

Completion date

2014-06-30

Last updated

2016-03-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pulmonary Hypertension

Keywords

Pulmonary arterial hypertension, cardiac MRI (magnetic resonance imaging), severity, prognosis

Brief summary

Pulmonary hypertension is a rare severe disease leading to cardiac insufficiency. Treatment depends on the severity of the disease. This study evaluates cardiac MRI for the assessment of pulmonary hypertension severity and identification of parameters useful for the follow-up in order to adapt the medical treatment to status of the patient. Evaluate if cardiac MRI can obviate right cardiac catheterization in the follow-up.

Detailed description

Thirty patients will be enrolled and followed for 1 year after their inclusion. Cardiac MRI will be performed at inclusion and at 3 months and 12 months. At the same periods, echocardiography and right heart catheterization will be performed too. Morphological and functional parameters will be studied with MRI and correlated to invasive parameters and echocardiography too. Morphological parameters are: volumes, cardiac cavities areas and ratios and position of the interventricular septum. Functional parameters are: ejection fractions of right and left cavities, flow in pulmonary artery, across mitral and tricuspid valves, temporal measurements in the pulmonary artery and auriculoventricular valves. The invasive measurements are considered as the gold standard for this study. The classification of the severity is defined according to the parameters from right cardiac catheterization (4 grades with severity increasing between 1 and 4).

Interventions

PROCEDUREMagnetic resonance imaging (MRI)

MRI cardiac and pulmonary with gadolinium

Study design

Allocation

Intervention model

SINGLE_GROUP

Primary purpose

DIAGNOSTIC

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Adults patients with pulmonary hypertension without specific treatment at inclusion * Etiologies include chronic embolic disease, systemic fibrosis, Gougerot Sjogren, drug induced hypertension, primary hypertension. * informed consent * affiliated to medical insurance.

Exclusion criteria

* Left cardiac disease responsible for pulmonary hypertension, congenital cardiopathies * Pulmonary functional tests with important impairment (decrease in TPCmore than 30%, decrease In VEMS more than 30% * Child * pregnancy * contraindications to MRI * without informed consent * without insurance

Design outcomes

Primary

Measure	Time frame	Description
Nuclear magnetic resonance imaging	Inclusion ; 3rd month ; 12th month	Correlation of cardiac results from the first MRI (Magnetic Resonance Imaging) to invasive measurements from the first or initial right heart catheterization and to echocardiography to know if cardiac MRI is able to predict severity of the disease

Countries

France

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026